Emergent BioSolutions (EBS) Misses Q1 EPS by 25c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.90 +0.64%
Revenue Growth %: +32.0%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +32.0%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of ($0.03), $0.25 worse than the analyst estimate of $0.22. Revenue for the quarter came in at $117.8 million versus the consensus estimate of $140.42 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
